Neoantigen cancer vaccine augments anti-CTLA-4 efficacy

Immune checkpoint inhibitors (ICI) based on anti-CTLA-4 (αCTLA-4) and anti-PD1 (αPD1) are being tested in combination with different therapeutic approaches including other immunotherapies such as neoantigen cancer vaccines (NCV). Here we explored, in two cancer murine models, different therapeutic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvatori, Erika, Lione, Lucia, Compagnone, Mirco, Pinto, Eleonora, Conforti, Antonella, Ciliberto, Gennaro, Aurisicchio, Luigi, Palombo, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810847/
https://www.ncbi.nlm.nih.gov/pubmed/35110563
http://dx.doi.org/10.1038/s41541-022-00433-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810847/
https://www.ncbi.nlm.nih.gov/pubmed/35110563
http://dx.doi.org/10.1038/s41541-022-00433-9

Ejemplares similares